Selective targeting of the tumour vasculature

ANZ Journal of Surgery

Volumn 78, Issue 11, 2008, Pages 955-967

  Chan, Lie S ^a   Daruwalla, Jurstine ^a   Christophi, Christopher ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Angiogenesis; Anti angiogenic agents; Chemotherapy; Clinical trials; Combretastatins; Neovasculature; OXi 4503; Solid organ malignancies; Tumour vasculature; Vascular disrupting agents

Indexed keywords

AE 941; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; BATIMASTAT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CILENGITIDE; CISPLATIN; COLCHICINE; COMBRETASTATIN; COMBRETASTATIN A1 PHOSPHATE; DOCETAXEL; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IMATINIB; IRINOTECAN; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY LM 609; N ACETYLPROLYLHISTIDYLSERYLCYSTEINYLASPARAGINE AMIDE; OXALIPLATIN; PACLITAXEL; PRINOMASTAT; TANOMASTAT; UNINDEXED DRUG; VASCULAR TARGETING AGENT;

AMINOTRANSFERASE BLOOD LEVEL; ANGIOGENESIS; ARTHRALGIA; BLEEDING; CARDIOTOXICITY; CELL SURVIVAL; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG INTOXICATION; DRUG MEGADOSE; DRUG POTENCY; DRUG TARGETING; FEBRILE NEUTROPENIA; GASTROINTESTINAL DISEASE; HEART DISEASE; HUMAN; HYPERTENSION; INTESTINE PERFORATION; LEUKOPENIA; LOW DRUG DOSE; MONOTHERAPY; NEOVASCULARIZATION (PATHOLOGY); NEUROPATHY; NEUTROPENIA; PROTEINURIA; RASH; REVIEW; SIDE EFFECT; SKIN DISEASE; THROMBOSIS; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME; VENOUS THROMBOEMBOLISM;

ANGIOGENESIS INHIBITORS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 54349097093     PISSN: 14451433     EISSN: 14452197     Source Type: Journal    
DOI: 10.1111/j.1445-2197.2008.04712.x     Document Type: Review

References (181)

1. Folkman J. Tumour angiogenesis: therapeutic implications. N. Engl. J. Med. 1971 285 : 1182 6.
2. Reinmuth N, Parikh AA, Ahmad SA et al. Biology of angiogenesis in tumours of the gastrointestinal tract. Microsc. Res. Tech. 2003 60 : 199 207.
3. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996 86 : 353 64.
4. Folkman J. Tumour angiogenesis. Adv. Cancer Res. 1985 43 : 175 203.
5. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000 407 : 249 57.
6. Carmeliet P. Angiogenesis in health and disease. Nat. Med. 2003 9 : 653 60.
7. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat. Med. 2003 9 : 677 84.
8. Ikeda E, Achen MG, Breier G, Risau W. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J. Biol. Chem. 1995 270 : 19761 6.
9. Harmey JH, Bouchier-Hayes D. Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: implications for anti-angiogenic therapy. Bioessays 2002 24 : 280 83.
10. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumours. Ann. Surg. 1972 175 : 409 16.
11. Malonne H, Langer I, Kiss R, Atassi G. Mechanisms of tumour angiogenesis and therapeutic implications: angiogenesis inhibitors. Clin. Exp. Metastasis 1999 17 : 1 14.
12. Gasparini G, Longo R, Toi M, Ferrara N. Angiogenic inhibitors: a new therapeutic strategy in oncology. Nat. Clin. Pract. Oncol. 2005 2 : 562 77.
13. Li J, Zhang YP, Kirsner RS. Angiogenesis in wound repair: angiogenic growth factors and the extracellular matrix. Microsc. Res. Tech. 2003 60 : 107 14.
14. Bruns CJ, Liu W, Davis DW et al. Vascular endothelial growth factor is an in vivo survival factor for tumour endothelium in a murine model of colorectal carcinoma liver metastases. Cancer 2000 89 : 488 99.
15. O'Reilly MS, Boehm T, Shing Y et al. Endostatin: an endogenous inhibitor of angiogenesis and tumour growth. Cell 1997 88 : 277 85.
16. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumours in mice. Nat. Med. 1996 2 : 689 92.
17. Drixler TA, Rinkes IH, Ritchie ED, van Vroonhoven TJ, Gebbink MF, Voest EE. Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy. Cancer Res. 2000 60 : 1761 5.
18. Mundhenke C, Thomas JP, Wilding G et al. Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin. Clin. Cancer Res. 2001 7 : 3366 74.
19. Kulke MH, Bergsland EK, Ryan DP et al. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumours. J. Clin. Oncol. 2006 24 : 3555 61.
20. Kurup A, Lin CW, Murry DJ et al. Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer: a phase II study from Indiana University. Ann. Oncol. 2006 17 : 97 103.
21. Zwick E, Bange J, Ullrich A. Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr. Relat. Cancer 2001 8 : 161 73.
22. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. 2003 21 : 60 65.
23. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J. Clin. Oncol. 2005 23 : 3706 12.
24. Kabbinavar FF, Schulz J, McCleod M et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J. Clin. Oncol. 2005 23 : 3697 705.
25. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004 350 : 2335 42.
26. Giantonio BJ. Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) in second- and third-line settings. Semin. Oncol. 2006 33 : S15 18.
27. Chen HX, Mooney M, Boron M et al. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI treatment referral center trial TRC-0301. J. Clin. Oncol. 2006 24 : 3354 60.
28. Ramaswamy B, Elias AD, Kelbick NT et al. Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin. Cancer Res. 2006 12 : 3124 9.
29. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 2003 349 : 427 34.
30. Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C, Greco A. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J. Clin. Oncol. 2005 23 : 7889 96.
31. Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 2004 22 : 2184 91.
32. Herbst RS, Johnson DH, Mininberg E et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. 2005 23 : 2544 55.
33. D'Adamo DR, Anderson SE, Albritton K et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J. Clin. Oncol. 2005 23 : 7135 42.
34. Kindler HL, Friberg G, Singh DA et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. 2005 23 : 8033 40.
35. Zhu AX, Blaszkowsky LS, Ryan DP et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 2006 24 : 1898 903.
36. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J. Clin. Oncol. 2003 21 : 2237 46.
37. Spigel DR, Hainsworth JD, Burkett ER et al. Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a minnie pearl cancer research network phase II trial. Clin. Lung Cancer 2005 7 : 127 32.
38. Niho S, Kubota K, Goto K et al. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study. J. Clin. Oncol. 2006 24 : 64 9.
39. Chen YM, Perng RP, Tsai CM. Gefitinib treatment is highly effective in non-small-cell lung cancer patients failing previous chemotherapy in Taiwan: a prospective phase II study. J. Chemother. 2005 17 : 679 84.
40. Suzuki R, Hasegawa Y, Baba K et al. A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer. Br. J. Cancer 2006 94 : 1599 603.
41. Inoue A, Suzuki T, Fukuhara T et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J. Clin. Oncol. 2006 24 : 3340 46.
42. Asahina H, Yamazaki K, Kinoshita I et al. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br. J. Cancer 2006 95 : 998 1004.
43. Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J. Clin. Oncol. 2004 22 : 777 84.
44. Hirsch FR, Varella-Garcia M, Bunn PA Jr. et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J. Clin. Oncol. 2006 24 : 5034 42.
45. Tsuboi M, Kato H, Nagai K et al. Gefitinib in the adjuvant setting: safety results from a phase III study in patients with completely resected non-small cell lung cancer. Anticancer Drugs 2005 16 : 1123 8.
46. Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J. Clin. Oncol. 2004 22 : 785 94.
47. Stinchcombe TE, Buzkova P, Choksi J et al. A phase I/II trial of weekly docetaxel and gefitinib in elderly patients with stage IIIB/IV non-small cell lung cancer. Lung Cancer 2006 52 : 305 11.
48. Fountzilas G, Pectasides D, Kalogera-Fountzila A et al. Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group. Breast Cancer Res. Treat. 2005 92 : 1 9.
49. Baselga J, Albanell J, Ruiz A et al. Phase II and tumour pharmacodynamic study of gefitinib in patients with advanced breast cancer. J. Clin. Oncol. 2005 23 : 5323 33.
50. Ciardiello F, Troiani T, Caputo F et al. Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. Br. J. Cancer 2006 94 : 1604 9.
51. Veronese ML, Sun W, Giantonio B et al. A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer. Br. J. Cancer 2005 92 : 1846 9.
52. Kindler HL, Friberg G, Skoog L, Wade-Oliver K, Vokes EE. Phase I/II trial of gefitinib and oxaliplatin in patients with advanced colorectal cancer. Am. J. Clin. Oncol. 2005 28 : 340 44.
53. Rothenberg ML, LaFleur B, Levy DE et al. Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. J. Clin. Oncol. 2005 23 : 9265 74.
54. Kuo T, Cho CD, Halsey J et al. Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. J. Clin. Oncol. 2005 23 : 5613 19.
55. Perez-Soler R. Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer. Clin. Lung Cancer 2004 6 (Suppl. 1 S20 23.
56. Giaccone G, Gallegos Ruiz M, Le Chevalier T et al. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin. Cancer Res. 2006 12 : 6049 55.
57. Milton DT, Azzoli CG, Heelan RT et al. A phase I/II study of weekly high-dose erlotinib in previously treated patients with non small cell lung cancer. Cancer 2006 107 : 1034 41.
58. Herbst RS, Prager D, Hermann R et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 2005 23 : 5892 9.
59. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J. Clin. Oncol. 2004 22 : 77 85.
60. Philip PA, Mahoney MR, Allmer C et al. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J. Clin. Oncol. 2005 23 : 6657 63.
61. Meyerhardt JA, Zhu AX, Enzinger PC et al. Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastatic colorectal cancer. J. Clin. Oncol. 2006 24 : 1892 7.
62. Seidman A, Hudis C, Pierri MK et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J. Clin. Oncol. 2002 20 : 1215 21.
63. Kantarjian HM, Talpaz M. Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias. Semin. Oncol. 2001 28 : 9 18.
64. Morishima Y, Ogura M, Nishimura M et al. Efficacy and safety of imatinib mesylate for patients in the first chronic phase of chronic myeloid leukemia: results of a Japanese phase II clinical study. Int. J. Hematol. 2004 80 : 261 6.
65. Krug LM, Crapanzano JP, Azzoli CG et al. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial. Cancer 2005 103 : 2128 31.
66. Eckel F, von Delius S, Mayr M et al. Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma. Oncology 2005 69 : 363 71.
67. Ugurel S, Hildenbrand R, Zimpfer A et al. Lack of clinical efficacy of imatinib in metastatic melanoma. Br. J. Cancer 2005 92 : 1398 405.
68. Wyman K, Atkins MB, Prieto V et al. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 2006 106 : 2005 11.
69. Heinrich MC, McArthur GA, Demetri GD et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumour). J. Clin. Oncol. 2006 24 : 1195 203.
70. Drevs J, Laus C, Mendinger M, Schmidt-Gersbach C, Unger C. Antiangiogenesis: current clinical data and future perspectives. Onkologie 2002 25 : 520 27.
71. Boedefeld WM 2nd., Bland KI, Heslin MJ. Recent insights into angiogenesis, apoptosis, invasion, and metastasis in colorectal carcinoma. Ann. Surg. Oncol. 2003 10 : 839 51.
72. Rundhaug JE. Matrix metalloproteinases and angiogenesis. J. Cell. Mol. Med. 2005 9 : 267 85.
73. Rothenberg ML, Nelson AR, Hande KR. New drugs on the horizon: matrix metalloproteinase inhibitors. Oncologist 1998 3 : 271 4.
74. Levi E, Fridman R, Miao HQ, Ma YS, Yayon A, Vlodavsky I. Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc. Natl Acad. Sci. U. S. A. 1996 93 : 7069 74.
75. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumour metastasis. Cancer Metastasis Rev. 2006 25 : 9 34.
76. Matsuyama Y, Takao S, Aikou T. Comparison of matrix metalloproteinase expression between primary tumours with or without liver metastasis in pancreatic and colorectal carcinomas. J. Surg. Oncol. 2002 80 : 105 10.
77. Wojtowicz-Praga S, Low J, Marshall J et al. Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer. Invest. New Drugs 1996 14 : 193 202.
78. Evans JD, Stark A, Johnson CD et al. A phase II trial of marimastat in advanced pancreatic cancer. Br. J. Cancer 2001 85 : 1865 70.
79. Groves MD, Puduvalli VK, Hess KR et al. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J. Clin. Oncol. 2002 20 : 1383 8.
80. Groves MD, Puduvalli VK, Conrad CA et al. Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status. J. Neurooncol. 2006 80 : 83 90.
81. Miller KD, Gradishar W, Schuchter L et al. A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer. Ann. Oncol. 2002 13 : 1220 24.
82. Sparano JA, Bernardo P, Stephenson P et al. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J. Clin. Oncol. 2004 22 : 4683 90.
83. Quirt I, Bodurth A, Lohmann R et al. Phase II study of marimastat (BB-2516) in malignant melanoma: a clinical and tumour biopsy study of the National Cancer Institute of Canada Clinical Trials Group. Invest. New Drugs 2002 20 : 431 7.
84. Rosenbaum E, Zahurak M, Sinibaldi V et al. Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trial. Clin. Cancer Res. 2005 11 : 4437 43.
85. Batist G, Patenaude F, Champagne P et al. Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels. Ann. Oncol. 2002 13 : 1259 63.
86. Latreille J, Batist G, Laberge F et al. Phase I/II trial of the safety and efficacy of AE-941 (Neovastat) in the treatment of non-small-cell lung cancer. Clin. Lung Cancer 2003 4 : 231 6.
87. Behrendt CE, Ruiz RB. Venous thromboembolism among patients with advanced lung cancer randomized to prinomastat or placebo, plus chemotherapy. Thromb. Haemost. 2003 90 : 734 7.
88. Bissett D, O'Byrne KJ, von Pawel J et al. Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. J. Clin. Oncol. 2005 23 : 842 9.
89. Heath EI, Burtness BA, Kleinberg L et al. Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma. Invest. New Drugs 2006 24 : 135 40.
90. Moore MJ, Hamm J, Dancey J et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 2003 21 : 3296 302.
91. Hirte H, Vergote IB, Jeffrey JR et al. A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study. Gynecol. Oncol. 2006 102 : 300 308.
92. Kurschat P, Mauch C. Mechanisms of metastasis. Clin. Exp. Dermatol. 2000 25 : 482 9.
93. McNeel DG, Eickhoff J, Lee FT et al. Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumour perfusion. Clin. Cancer Res. 2005 11 : 7851 60.
94. Friess H, Langrehr JM, Oettle H et al. A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. BMC Cancer 2006 6 : 285 97.
95. Cianfrocca ME, Kimmel KA, Gallo J et al. Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours. Br. J. Cancer 2006 94 : 1621 6.
96. Gutheil JC, Campbell TN, Pierce PR et al. Targeted antiangiogenic therapy for cancer using vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin. Cancer Res. 2000 6 : 3056 61.
97. Bicknell R. Mechanistic insights into tumour angiogenesis. In : Bicknell R, Lewis CE, Ferrara N (eds). Tumour Angiogenesis. USA : Oxford University Press, 1997 19 28.
98. Fiedler W, Mesters R, Tinnefeld H et al. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 2003 102 : 2763 7.
99. Kuenen BC, Tabernero J, Baselga J et al. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clin. Cancer Res. 2003 9 : 1648 55.
100. Stadler WM, Kuzel T, Shapiro C, Sosman J, Clark J, Vogelzang NJ. Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J. Clin. Oncol. 1999 17 : 2541 5.
101. Zangari M, Anaissie E, Stopeck A et al. Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin. Cancer Res. 2004 10 : 88 95.
102. McDonnell CO, Holden G, Sheridan ME et al. Improvement in efficacy of chemoradiotherapy by addition of an antiangiogenic agent in a murine tumour model. J. Surg. Res. 2004 116 : 19 23.
103. Jain RK. Normalization of tumour vasculature: an emerging concept in antiangiogenic therapy. Science 2005 307 : 58 62.
104. Morioka H, Weissbach L, Vogel T et al. Antiangiogenesis treatment combined with chemotherapy produces chondrosarcoma necrosis. Clin. Cancer Res. 2003 9 : 1211 17.
105. Huber PE, Bischof M, Jenne J et al. Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Res. 2005 65 : 3643 55.
106. Albertsson P, Lennernas B, Norrby K. Chemotherapy and antiangiogenesis: drug-specific effects on microvessel sprouting. APMIS 2003 111 : 995 1003.
107. McCarthy M. Antiangiogenesis drug promising for metastatic colorectal cancer. Lancet 2003 361 : 1959.
108. Kerbel RS. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 2006 312 : 1171 5.
109. Wu Y, Yang L, Hu B et al. Synergistic anti-tumour effect of recombinant human endostatin adenovirus combined with gemcitabine. Anticancer Drugs 2005 16 : 551 7.
110. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumours. Cancer Res. 2004 64 : 3731 6.
111. Roman CD, Choy H, Nanney L et al. Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats. J. Surg. Res. 2002 105 : 43 7.
112. Thompson WD, Li WW, Maragoudakis M. The clinical manipulation of angiogenesis: pathology, side-effects, surprises, and opportunities with novel human therapies. J. Pathol. 1999 187 : 503 10.
113. Scappaticci FA, Fehrenbacher L, Cartwright T et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J. Surg. Oncol. 2005 91 : 173 80.
114. Thornton AD, Ravn P, Winslet M, Chester K. Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer. Br. J. Surg. 2006 93 : 1456 63.
115. Denekamp J. Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br. J. Cancer 1982 45 : 136 9.
116. Hobson B, Denekamp J. Endothelial proliferation in tumours and normal tissues: continuous labelling studies. Br. J. Cancer 1984 49 : 405 13.
117. Jain RK. Determinants of tumour blood flow: a review. Cancer Res. 1988 48 : 2641 58.
118. Bloemendal HJ, Logtenberg T, Voest EE. New strategies in anti-vascular cancer therapy. Eur. J. Clin. Invest. 1999 29 : 802 9.
119. Denekamp J, Hobson B. Endothelial-cell proliferation in experimental tumours. Br. J. Cancer 1982 46 : 711 20.
120. Sheng Y, Hua J, Pinney KG et al. Combretastatin family member OXI4503 induces tumour vascular collapse through the induction of endothelial apoptosis. Int. J. Cancer 2004 111 : 604 10.
121. Chaplin D, Trotter M, Dougherty GJ. Microregional tumour blood flow: heterogeneity and therapeutic significance. In : Bicknell R, Lewis CE, Ferrara N (eds). Tumour Angiogenesis. Oxford University Press, 1997 61 70.
122. Kerbel RS. A cancer therapy resistant to resistance. Nature 1997 390 : 335 6.
123. O'Hanlon LH. Taking down tumours: vascular disrupting agents entering clinical trials. J. Natl. Cancer Inst. 2005 97 : 1244 5.
124. Siemann DW, Chaplin DJ, Horsman MR. Vascular-targeting therapies for treatment of malignant disease. Cancer 2004 100 : 2491 9.
125. Siemann DW. Vascular targeting agents. In : Horizons in Cancer Therapeutics: From Benchside to Bedside. West Conshohocken, PA : Meniscus Education Institute, 2002 4 14.
126. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin. Cancer Res. 2004 10 : 415 27.
127. Burrows FJ, Thorpe PE. Eradication of large solid tumours in mice with an immunotoxin directed against tumour vasculature. Proc. Natl. Acad. Sci. U. S. A. 1993 90 : 8996 9000.
128. Selvaggi K, Saria EA, Schwartz R et al. Phase I/II study of murine monoclonal antibody-ricin A chain (XOMAZYME-Mel) immunoconjugate plus cyclosporine A in patients with metastatic melanoma. J. Immunother. 1993 13 : 201 7.
129. Oratz R, Speyer JL, Wernz JC et al. Antimelanoma monoclonal antibody-ricin A chain immunoconjugate (XMMME-001-RTA) plus cyclophosphamide in the treatment of metastatic malignant melanoma: results of a phase II trial. J. Biol. Response Modif. 1990 9 : 345 54.
130. Zalcberg JR, Pietersz G, Toohey B et al. A phase I/II study of the intralesional injection of ricin-monoclonal antibody conjugates in patients with hepatic metastases. Eur. J. Cancer. 1994 30A : 1227 31.
131. Multani PS, O'Day S, Nadler LM, Grossbard ML. Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma. Clin. Cancer Res. 1998 4 : 2599 604.
132. Fidias P, Grossbard M, Lynch TJ Jr. A phase II study of the immunotoxin N901-blocked ricin in small-cell lung cancer. Clin. Lung Cancer 2002 3 : 219 22.
133. Kerr DJ, Maughan T, Newlands E et al. Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma. Br. J. Cancer 1989 60 : 104 6.
134. Kaye SB, Clavel M, Dodion P et al. Phase II trials with flavone acetic acid (NCS. 347512, LM975) in patients with advanced carcinoma of the breast, colon, head and neck and melanoma. Invest. New Drugs 1990 8 (Suppl. 1 S95 9.
135. Thatcher N, Dazzi H, Mellor M et al. Recombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: a phase II study. Br. J. Cancer 1990 61 : 618 21.
136. Jameson MB, Thompson PI, Baguley BC et al. Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br. J. Cancer 2003 88 : 1844 50.
137. Rustin GJ, Bradley C, Galbraith S et al. 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study. Br. J. Cancer 2003 88 : 1160 67.
138. Beerepoot LV, Radema SA, Witteveen EO et al. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumours. J. Clin. Oncol. 2006 24 : 1491 8.
139. Dowlati A, Robertson K, Cooney M et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res. 2002 62 : 3408 16.
140. Rustin GJ, Galbraith SM, Anderson H et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J. Clin. Oncol. 2003 21 : 2815 22.
141. Stevenson JP, Rosen M, Sun W et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumour blood flow. J. Clin. Oncol. 2003 21 : 4428 38.
142. Vincent L, Kermani P, Young LM et al. Combretastatin A4 phosphate induces rapid regression of tumour neovessels and growth through interference with vascular endothelial-cadherin signaling. J. Clin. Invest. 2005 115 : 2992 3006.
143. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat. Rev. Cancer 2005 5 : 423 35.
144. Kanthou C, Tozer GM. The tumour vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 2002 99 : 2060 69.
145. Murata R, Siemann DW, Overgaard J, Horsman MR. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumours. Radiother. Oncol. 2001 60 : 155 61.
146. Bilenker JH, Flaherty KT, Rosen M et al. Phase I trial of combretastatin a-4 phosphate with carboplatin. Clin. Cancer Res. 2005 11 : 1527 33.
147. Corbett TH, Bissery MC, Wozniak A et al. Activity of flavone acetic acid (NSC-347512) against solid tumours of mice. Invest. New Drugs 1986 4 : 207 20.
148. Mahadevan V, Malik ST, Meager A, Fiers W, Lewis GP, Hart IR. Role of tumour necrosis factor in flavone acetic acid-induced tumour vasculature shutdown. Cancer Res. 1990 50 : 5537 42.
149. Thomsen LL, Ching LM, Zhuang L, Gavin JB, Baguley BC. Tumour-dependent increased plasma nitrate concentrations as an indication of the antitumour effect of flavone-8-acetic acid and analogues in mice. Cancer Res. 1991 51 : 77 81.
150. Baguley BC. Antivascular therapy of cancer: DMXAA. Lancet Oncol. 2003 4 : 141 8.
151. Kerr DJ, Kaye SB. Flavone acetic acid-preclinical and clinical activity. Eur. J. Cancer Clin. Oncol. 1989 25 : 1271 2.
152. Kerr DJ, Kaye SB, Cassidy J et al. Phase I and pharmacokinetic study of flavone acetic acid. Cancer Res. 1987 47 : 6776 81.
153. Li Q, Sham HL, Rosenberg SH. Anti mitotic agents. In : Greenlee W (ed). Annual Reports in Medicinal Chemistry, 34. USA : Academic Press, 1999 139 48.
154. Downing KH, Nogales E. Tubulin and microtubule structure. Curr. Opin. Cell Biol. 1998 10 : 16 22.
155. Nogales E. Structural insights into microtubule function. Annu. Rev. Biochem. 2000 69 : 277 302.
156. Jordan MA, Thrower D, Wilson L. Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer Res. 1991 51 : 2212 22.
157. Seed L, Slaughter D, Limarzi L. Effect of Colchicine on human carcinoma. Surgery 1939 7 : 696 709.
158. Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS, Garcia-Kendall D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 1989 45 : 209 11.
159. Pettit GR, Temple C Jr., Narayanan VL et al. Antineoplastic agents 322. Synthesis of combretastatin A-4 prodrugs. Anticancer Drug Des. 1995 10 : 299 309.
160. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumour vasculature. Cancer Res. 1997 57 : 1829 34.
161. Tozer GM. Tumour Microcirculation. UK : Gray Cancer Institution, 2000.
162. Wehbe H, Kearney CM, Pinney KG. Combretastatin A-4 resistance in H460 human lung carcinoma demonstrates distinctive alterations in beta-tubulin isotype expression. Anticancer Res. 2005 25 : 3865 70.
163. Tint IS, Bershadsky AD, Gelfand IM, Vasiliev JM. Post-translational modification of microtubules is a component of synergic alterations of cytoskeleton leading to formation of cytoplasmic processes in fibroblasts. Proc. Natl. Acad. Sci. U. S. A. 1991 88 : 6318 22.
164. Mandelkow E, Mandelkow EM. Microtubules and microtubule-associated proteins. Curr. Opin. Cell Biol. 1995 7 : 72 81.
165. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr. Opin. Genet. Dev. 2005 15 : 102 11.
166. Tanaka K, Takai Y. Control of reorganization of the actin cytoskeleton by Rho family small GTP-binding proteins in yeast. Curr. Opin. Cell Biol. 1998 10 : 112 16.
167. Narumiya S, Ishizaki T, Watanabe N. Rho effectors and reorganization of actin cytoskeleton. FEBS Lett. 1997 410 : 68 72.
168. Tozer GM, Prise VE, Wilson J et al. Mechanisms associated with tumour vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res. 2001 61 : 6413 22.
169. Galbraith SM, Chaplin DJ, Lee F et al. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res. 2001 21 : 93 102.
170. Grosios K, Holwell SE, McGown AT, Pettit GR, Bibby MC. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br. J. Cancer 1999 81 : 1318 27.
171. Chaplin DJ, Hill SA. The development of combretastatin A4 phosphate as a vascular targeting agent. Int. J. Radiat. Oncol. Biol. Phys. 2002 54 : 1491 6.
172. Li L, Rojiani A, Siemann DW. Targeting the tumour vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 1998 42 : 899 903.
173. Grosios K, Loadman PM, Swaine DJ, Pettit GR, Bibby MC. Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res. 2000 20 : 229 33.
174. Eikesdal HP, Schem BC, Mella O, Dahl O. The new tubulin-inhibitor combretastatin A-4 enhances thermal damage in the BT4An rat glioma. Int. J. Radiat. Oncol. Biol. Phys. 2000 46 : 645 52.
175. Nelkin BD, Ball DW. Combretastatin A-4 and doxorubicin combination treatment is effective in a preclinical model of human medullary thyroid carcinoma. Oncol. Rep. 2001 8 : 157 60.
176. Pedley RB, Hill SA, Boxer GM et al. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate. Cancer Res. 2001 61 : 4716 22.
177. Eikesdal HP, Bjerkvig R, Raleigh JA, Mella O, Dahl O. Tumour vasculature is targeted by the combination of combretastatin A-4 and hyperthermia. Radiother. Oncol. 2001 61 : 313 20.
178. Murata R, Overgaard J, Horsman MR. Combretastatin A-4 disodium phosphate: a vascular targeting agent that improves that improves the anti-tumour effects of hyperthermia, radiation, and mild thermoradiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2001 51 : 1018 24.
179. Eikesdal HP, Bjerkvig R, Mella O, Dahl O. Combretastatin A-4 and hyperthermia; a potent combination for the treatment of solid tumours. Radiother. Oncol. 2001 60 : 147 54.
180. Li L, Rojiani AM, Siemann DW. Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma. Acta Oncol. 2002 41 : 91 7.
181. Horsman MR, Murata R. Combination of vascular targeting agents with thermal or radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 2002 54 : 1518 23.